Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Safety and efficacy of continuous glucose monitoring devices in individuals with diabetes undergoing hyperbaric oxygen therapy: a scoping review

View through CrossRef
Introduction: Continuous glucose monitoring devices (CGMs) have emerged as an effective approach to optimise glycaemic control for individuals living with diabetes mellitus. Despite CGMs offering improved patient satisfaction and quality of life, they have been primarily validated for outpatient and home use. This has posed a challenge for patients and providers who wish to incorporate CGMs into clinical settings such as hyperbaric oxygen therapy (HBOT). Those with advanced diabetes mellitus who have diabetic foot ulcers that are refractory to treatment are among the most prevalent users of HBOT. However, those who prefer to use their CGM during HBOT face uncertainty regarding the accuracy and safety of their device under hyperbaric conditions. Methods: The product specifications of commonly used CGMs were collated. In addition, a scoping review of the literature was conducted where Medline, Embase, and Scopus were searched for reports that assess the accuracy or safety of CGMs in hyperbaric conditions. Results: The product specifications of commonly used CGMs by Dexcom, Abbott, Medtronic, and Senseonics demonstrate a maximum validated pressure of approximately 106 kPa (1.06 atmospheres absolute). Our literature search identified five reports, of which four focused on accuracy and one focused on safety of CGMs in hyperbaric conditions. Treatments were conducted in multiplace chambers and cumulatively described 39 participants, of whom 12 have diabetes. Although heterogeneous in nature, the reports generally supported the safety and accuracy of CGMs in hyperbaric conditions. Conclusions: The safety and accuracy of using CGMs during HBOT warrants further investigation. CGMs have not been validated for repeated exposure to hyperbaric conditions and should not be used in oxygen pressurised monoplace chambers until further safety data is available. We provide practical recommendations for use of CGMs in multiplace chambers.
Title: Safety and efficacy of continuous glucose monitoring devices in individuals with diabetes undergoing hyperbaric oxygen therapy: a scoping review
Description:
Introduction: Continuous glucose monitoring devices (CGMs) have emerged as an effective approach to optimise glycaemic control for individuals living with diabetes mellitus.
Despite CGMs offering improved patient satisfaction and quality of life, they have been primarily validated for outpatient and home use.
This has posed a challenge for patients and providers who wish to incorporate CGMs into clinical settings such as hyperbaric oxygen therapy (HBOT).
Those with advanced diabetes mellitus who have diabetic foot ulcers that are refractory to treatment are among the most prevalent users of HBOT.
However, those who prefer to use their CGM during HBOT face uncertainty regarding the accuracy and safety of their device under hyperbaric conditions.
Methods: The product specifications of commonly used CGMs were collated.
In addition, a scoping review of the literature was conducted where Medline, Embase, and Scopus were searched for reports that assess the accuracy or safety of CGMs in hyperbaric conditions.
Results: The product specifications of commonly used CGMs by Dexcom, Abbott, Medtronic, and Senseonics demonstrate a maximum validated pressure of approximately 106 kPa (1.
06 atmospheres absolute).
Our literature search identified five reports, of which four focused on accuracy and one focused on safety of CGMs in hyperbaric conditions.
Treatments were conducted in multiplace chambers and cumulatively described 39 participants, of whom 12 have diabetes.
Although heterogeneous in nature, the reports generally supported the safety and accuracy of CGMs in hyperbaric conditions.
Conclusions: The safety and accuracy of using CGMs during HBOT warrants further investigation.
CGMs have not been validated for repeated exposure to hyperbaric conditions and should not be used in oxygen pressurised monoplace chambers until further safety data is available.
We provide practical recommendations for use of CGMs in multiplace chambers.

Related Results

Pregnancy and Challenging Transient Anti-GAD65 Positivity: A Case Report with Literature Review
Pregnancy and Challenging Transient Anti-GAD65 Positivity: A Case Report with Literature Review
Abstract Introduction During pregnancy, women may develop blood glucose abnormalities like gestational diabetes mellitus (GDM) or, rarely, type 1 diabetes (T1D), which can lead to ...
N-terminal pro-B-type natriuretic peptide levels increases after hyperbaric oxygen therapy in diabetic patients
N-terminal pro-B-type natriuretic peptide levels increases after hyperbaric oxygen therapy in diabetic patients
Purpose Diabetic patients receive hyperbaric oxygen therapy for non-healing lower extremity ulcers. Exposure to hyperbaric hyperoxia during hyperbaric oxygen therapy may affect car...
Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss – A Comorbidity Lens
Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss – A Comorbidity Lens
Leder Macek AJ, Wang RS, Cottrell J, Kay-Rivest E, McMenomey SO, Roland Jr. T, Ross FL. Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss – A Comorbidity Lens. Unders...
Undiagnosed Diabetes in Acute Coronary Syndrome: A Silent Threat in Pakistan
Undiagnosed Diabetes in Acute Coronary Syndrome: A Silent Threat in Pakistan
Diabetes mellitus (DM) has emerged as one of the most pressing public health challenges globally, and Pakistan stands among the countries most severely affected. With rising urbani...
Safety and performance of intravenous pumps and syringe drivers in hyperbaric environments
Safety and performance of intravenous pumps and syringe drivers in hyperbaric environments
Introduction: Critically ill patients require continuation of their care when receiving hyperbaric oxygen treatment. This care may be facilitated via portable electrically powered ...
Hyperbaric oxygen but not hyperbaric air increases insulin sensitivity in men with type 2 diabetes mellitus
Hyperbaric oxygen but not hyperbaric air increases insulin sensitivity in men with type 2 diabetes mellitus
Introduction: We have previously shown that hyperbaric oxygen treatment (HBOT) increased insulin sensitivity in men who were obese or overweight, both with and without type 2 diabe...
Therapeutic effects of hyperbaric oxygen
Therapeutic effects of hyperbaric oxygen
Hyperbaric oxygen therapy refers to inhalation of pure oxygen in a closed chamber. Hyperbaric oxygen has a therapeutic effect in numerous pathological conditions, such as decompres...

Back to Top